Getting More From Your Biotech IR Calendar in 2026
After a bullish JPMorgan Healthcare Conference, investor interest in biotech is returning. Here are practical ways management teams can maximize their IR calendars by working smarter and selectively expanding availability.
Following a highly productive and bullish 2026 JP Morgan conference, investor interest in the biotech sector has only increased. Given this growing appeal, it’s logical for managements to think about how to maximize the impact of their shareholder focused efforts and whether they should be broadening their availability. Below are some tips for getting the most from your IR calendar in this new environment by working both harder and smarter.
Selectively Add to Your Availability: For years, biotech IR has been pushing on a string. That is not likely the case in 2026. There will undoubtedly be many new faces at conferences and on NDR schedules. In the current market, the return on your time has improved substantially. So, get out there a bit more! Adding a few additional NDR dates and another conference or two makes sense to meeting this broadening demand.
Identify the New Investors You Want to Meet: A bull market will draw a much larger pool of investors to biotech than the industry has seen in some time. Many of them will be unfamiliar to even experienced management teams. Don’t just wait to see who’s on your next conference schedule, try to find some new targets yourself. Shareholder lists of more mature biotech and veteran sell side analysts with long memories are two good sources of information about investors who may be coming back to biotech for the first time in a while.
Reach out to Investors Proactively: Investors who haven’t been around the space in a while also need some guidance on how to allocate their time. Make it easy for them to find you by finding them. Ask for a meeting.
Explain the Upside Opportunity First: Investors are looking to play offense in the space for the first time in a while. Start any presentation by discussing why you can deliver upside to their portfolio.
Investors are building lists of potential new holdings very quickly. They (and their bosses) will undoubtedly have questions and want more answers before buying any stock. Make it easy for them to buy yours by getting them the information they need to make a decision.
Biotech hasn’t seen a sustained rally in almost a decade (2020-21 doesn’t count!). To be one of the winners in this rally means to change some long lived IR strategies and behaviors. In practice, that means focusing on a few core priorities:
Recognize that the paradigm has shifted
Identify and target the new market entrants
Understand their motivations
Make it easy for them to pick your stock from amongst all potential choices